Placeholder

The Fourth Tier: Tighter Control of Specialty Drugs

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1146. Category: .

Product Description

Managed care organizations are tackling the rising costs and expanding use of specialty products. Specialty drugs, injectable biologics, and other higher-cost drugs that require close supervision and monitoring are the fastest-growing segment of the overall pharmaceutical space.
The average annual increase in drug cost expenditures reported in 2007 was 6.9%, according to the Pharmacy Benefit Management Institute‚Äôs (PBMI) 2007 Prescription Drug Benefit Cost and Plan Design Report released in October 2007…

Sidebars:
The top six specialty categories
2007 to 2010 Forecast for selected specialty therapy classes

Experts on this Topic
Michael Goodman. VP, Research Products, AVOS Life Sciences, Raleigh, N.C.; AVOS Life Sciences is a boutique advisory and research products company. For more information, visit avoslifesciences.com.
Michael Jacobs. National Clinical Practice Leader, Buck Consultants LLC, New York; Buck Consultants provides human resource and benefits consulting through more than 1,500 professionals worldwide. For more information, visit buckconsultants.com.
Tony Lanzone. VP, Trade and Distribution Practice, Campbell Alliance, Raleigh, N.C.; Campbell Alliance is a management consulting firm
specializing in the pharmaceutical and biotechnology industries. For more information, visit campbellalliance.com.

FEEDBACK